Vimta Labs Ltd, founded in 1984 and headquartered in Hyderabad, India, is a leading contract research and testing organization providing comprehensive scientific, technical, and regulatory expertise to support all stages of drug development and manufacturing processes. The company has been supporting national and overseas companies for more than three decades for their third-party testing, research, and outsourcing needs.
Vimta Labs operates as a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. The company supports the needs of more than 300 bio/pharmaceutical companies across the globe, ranging from virtual to large pharma and biopharma companies.
Vimta Labs is engaged in the business of contract research and testing in the fields of biologics, small molecules, agro-chemicals, food & beverages, electronics, clinical diagnostics, medical devices, home and personal care products, and environment testing. The company's services portfolio includes testing and contract research services in clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies.
The service portfolio encompasses preclinical and clinical research, and cGMP laboratory services including method development and validations, microbiology, stability testing, extractables and leachables, process validation, quality control, and physical characterization. The company is one of the few labs to be accredited by GMP, GCP and GLP, has an in-house laboratory for pathology services which is NABL and CAP accredited, and its facility for pre-clinical services is AAALAC certified. Vimta has been successfully audited by 70+ regulatory audits and undergone 30+ regulatory inspections, including USFDA, EU, WHO, ANVISA, NRPA, and MHRA.
Vimta Labs reported a 36.8% rise in net profit to Rs 66.75 crore on a 19.1% increase in total income to Rs 348.22 crore in FY25 as compared with FY24. For the full year ended March 2025, net profit rose 64.20% to Rs 67.34 crore against Rs 41.01 crore in the previous year, while sales increased 19.19% to Rs 343.98 crore from Rs 288.60 crore in the previous year.
In Q4 FY25, net profit rose 48.34% to Rs 18.32 crore compared to Rs 12.35 crore in Q4 FY24, with sales increasing 29.85% to Rs 94.44 crore from Rs 72.73 crore in the corresponding quarter. EBITDA margin was 36.1% in Q4 FY25 compared to 36.0% in Q4 FY24, while profit before tax stood at Rs 25.03 crore, up by 39.5% from Rs 17.94 crore in Q4 FY24.
• Q4 FY2024-25 Performance: Net Profit of Rs 18.32 crore (up 48.34%), Sales of Rs 94.44 crore (up 29.85%)
• FY2024-25 Performance: Net Profit of Rs 67.34 crore (up 64.20%), Sales of Rs 343.98 crore (up 19.19%)
• Total Income FY2024-25: Rs 348.22 crore
• Market Capitalization: ₹2,006 crore (as of latest data)
• Promoter Holding: 36.70% (as of March 2025)
• Total Employees: 1,428
In June 2025, Vimta Labs allotted 2.22 crore bonus shares in a 1:1 ratio, increasing the paid-up capital to 8.90 crore shares. The company's board approved a dividend of Rs 2 per equity share for the financial year 2024-25.
In April 2025, the board approved the company's foray into Biologics Contract Research and Development with an investment of Rs 50 crore, which will help Vimta enter the growing CDMO business of biologics and peptides. The board also approved increasing the company's borrowing powers up to Rs 300 crore, subject to shareholder approval at the annual general meeting.
As of March 31, 2025, total debt stood at Rs 8.5 crore, while cash and cash equivalents, including bank balance, stood at Rs 32.9 crore. The company has significantly reduced debt and is almost debt-free, indicating a strong financial position.
Vimta Labs continues to strengthen its position as a leading contract research organization in India, with consistent financial growth, strategic expansions into new business segments, and strong regulatory compliance track record positioning it well for future growth opportunities in the pharmaceutical and healthcare sectors.
